Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
New Advances of Proteins in Neuroinflammation
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

New Advances of Proteins in Neuroinflammation

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".

Deadline for manuscript submissions: closed (30 September 2024) | Viewed by 3209

Special Issue Editors

Prof. Dr. Fabrizio Michetti

E-Mail
Guest Editor
Department of Neuroscience, Università Cattolica S. Cuore, 00168 Rome, Italy
Interests: neurodegeneration; neuroinflammation; multiple sclerosis; amyotrophic lateral sclerosis; animal models of neural diseases; neural biomarkers; calcium-binding neuroproteins; S100B protein
Special Issues, Collections and Topics in MDPI journals
Dr. M. Elisabetta Clementi

E-Mail Website
Guest Editor
National Research Council (CNR), Istituto di Scienze e Tecnologie Chimiche “Giulio Natta” (SCITEC)—c/o Istituto di Biochimica e Biochimica Clinica Università Cattolica del Sacro Cuore, Largo F. Vito 1, 00168 Rome, Italy
Interests: apoptosis; oxidative stress; nutraceutical
Special Issues, Collections and Topics in MDPI journals
Dr. Gabriele Di Sante

E-Mail Website
Guest Editor
Department of Medicine and Surgery, Section of Human, Clinical and Forensic Anatomy, Università degli Studi di Perugia, 06132 Perugia, Italy
Interests: immunopathology; autoimmune disorders; host-pathogen interaction; immunotherapy; neuroimmunology; multiple sclerosis; rheumatoid arthritis; oncoimmunology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Inflammatory processes are known to play an active role in a large part of neural disorders, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy, acute traumatic and vascular brain injury.

Among the molecules actively involved in neuroinflammatory processes, proteins—known to be required for the structure, function, and regulation of different tissues and organs in health and disease due to their structural complexity—are regarded as playing a crucial role. Damage/Danger-Associated Molecular Pattern proteins and inflammasomes are protein molecules currently regarded as explicitly involved in these physiopathological mechanisms.

Thus, a deeper understanding of the role of proteins in neuroinflammatory processes would significantly contribute to the knowledge of these disorders and would help to identify possible therapeutic targets.

In this Special Issue, we aim to cover all aspects of the current landscape of research in the role of protein molecules involved in neuroinflammatory processes as pathogenic effectors, and as a consequence as possible therapeutic targets, but also as diagnostic, prognostic and predictive biomarkers.

Prof. Dr. Fabrizio Michetti
Dr. M. Elisabetta Clementi
Dr. Gabriele Di Sante
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neuroinflammation
  • DAMPs
  • inflammasome
  • cyokines
  • neuroproteins

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 1397 KiB  
Article
Multiple Sclerosis Onset before and after COVID-19 Vaccination: Can HLA Haplotype Be Determinant?
by Assunta Bianco, Gabriele Di Sante, Francesca Colò, Valeria De Arcangelis, Alessandra Cicia, Paola Del Giacomo, Maria De Bonis, Tommaso Giuseppe Morganti, Vincenzo Carlomagno, Matteo Lucchini, Angelo Minucci, Paolo Calabresi and Massimiliano Mirabella
Int. J. Mol. Sci. 2024, 25(8), 4556; https://doi.org/10.3390/ijms25084556 - 22 Apr 2024
Viewed by 2776
Abstract
A few cases of multiple sclerosis (MS) onset after COVID-19 vaccination have been reported, although the evidence is insufficient to establish causality. The aim of this study is to compare cases of newly diagnosed relapsing–remitting MS before and after the outbreak of the [...] Read more.
A few cases of multiple sclerosis (MS) onset after COVID-19 vaccination have been reported, although the evidence is insufficient to establish causality. The aim of this study is to compare cases of newly diagnosed relapsing–remitting MS before and after the outbreak of the COVID-19 pandemic and the impact of COVID-19 vaccination. Potential environmental and genetic predisposing factors were also investigated, as well as clinical patterns. This is a single-centre retrospective cohort study including all patients who presented with relapsing–remitting MS onset between January 2018 and July 2022. Data on COVID-19 vaccination administration, dose, and type were collected. HLA-DRB1 genotyping was performed in three subgroups. A total of 266 patients received a new diagnosis of relapsing–remitting MS in our centre, 143 before the COVID-19 pandemic (until and including March 2020), and 123 during the COVID-19 era (from April 2020). The mean number of new MS onset cases per year was not different before and during the COVID-19 era and neither were baseline patients’ characteristics, type of onset, clinical recovery, or radiological patterns. Fourteen (11.4%) patients who subsequently received a new diagnosis of MS had a history of COVID-19 vaccination within one month before symptoms onset. Patients’ characteristics, type of onset, clinical recovery, and radiological patterns did not differ from those of patients with non-vaccine-related new diagnoses of MS. The allele frequencies of HLA-DRB1*15 were 17.6% and 22.2% in patients with non-vaccine-related disease onset before and during the COVID-19 era, respectively, while no case of HLA-DRB1*15 was identified among patients with a new diagnosis of MS post-COVID-19 vaccine. In contrast, HLA-DRB1*08+ or HLA-DRB1*10+ MS patients were present only in this subgroup. Although a causal link between COVID-19 vaccination and relapsing–remitting MS cannot be detected, it is interesting to note and speculate about the peculiarities and heterogeneities underlying disease mechanisms of MS, where the interactions of genetics and the environment could be crucial also for the follow-up and the evaluation of therapeutic options. Full article
(This article belongs to the Special Issue New Advances of Proteins in Neuroinflammation)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop